Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMH Trial: Basal-Bolus vs Sliding Scale Insulin in Hospitalized Patients
NCT01136746Phase 3
Key facts
- Status
- Terminated
- Start
- Mar 2011
- Primary completion
- Nov 2011
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Modality
- Recombinant Proteins and Enzymes
- Conditions
- hyperglycemia
01
Overview
Phase 3, randomised, open-label trial of insulin glargine and insulin lispro in hyperglycemia (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Mean Plasma Glucose and Percentage of Capillary Plasma Glucose Measurements Within Range. Started Mar 2011; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Sliding Scale
Human regular insulin 4 times daily as needed
Basal-Bolus
Insulin glargine once daily + Insulin lispro 3-4 times daily
03
Who it enrols
Adult non-critically ill inpatients with hyperglycemia (140-400 mg/dL) and no known history of diabetes.
04
Endpoints
Primary
Mean Plasma Glucose
Percentage of Capillary Plasma Glucose Measurements Within Range
Secondary
Incidence of Hypoglycemia and Severe Hypoglycemia Episodes
Length of Hospital Stay Post-randomization
Total Daily Dose of Insulin
Treatment-emergent Adverse Events
Beyond the preview
Go deeper on NCT01136746.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01136746.